Does a positive IgA result mean the patient has a food allergy?

No. A positive IgA titre indicates mucosal immune activation but is not diagnostic of IgE-mediated allergy, coeliac disease, or any specific clinical intolerance. It is used as a guide for empirical elimination and reintroduction, not as stand-alone proof of disease.

Can the test be used to diagnose coeliac disease?

No. Coeliac disease requires specific serology (tissue transglutaminase IgA, endomysial IgA) and duodenal biopsy. This panel includes wheat and gluten but is not a substitute for standard coeliac testing and should not be used to diagnose or exclude coeliac disease.

Why does the test require the patient to be eating the foods normally?

IgA titres reflect recent and repetitive mucosal exposure. If a food has been eliminated for weeks or months, IgA levels may fall and yield a false-negative result, so normal dietary intake is needed for accurate assessment.

What should be done if the patient has selective IgA deficiency?

Selective IgA deficiency, affecting roughly 1 in 300–700 individuals, renders the test uninformative. Total serum IgA should be measured; if deficient, consider IgG-based food panels or focus on clinical elimination–rechallenge protocols rather than serology.

Is this test accepted by mainstream gastroenterology and allergy guidelines?

No. Major gastroenterology and allergy societies do not endorse IgA or IgG food panels for diagnosis, and evidence linking elevated IgA to clinical intolerance is limited. The test is a functional medicine tool used to guide personalised dietary intervention when conventional workup is unrevealing.

Why does reactivity to many foods raise concern?

Reactivity to more than 20–30 foods suggests non-specific polyclonal immune activation, specimen artifact, acute inflammation, or increased permeability rather than true multiple food intolerances. Clinical correlation and repeat testing after gut-restoration therapy may be warranted.

How long does it take to receive results?

Results are typically available 10–14 business days from specimen receipt at Alletess Medical Laboratory, though turnaround may be longer during peak periods or if technical repeat is required.

BML-FSA-010food sensitivity allergyUSA

184 IgA Food Sensitivity Panel

Q: How are the results used clinically?

Moderate or high IgA titres to specific foods are used to prioritise a time-limited elimination trial (typically 4–12 weeks), followed by structured reintroduction and symptom tracking. The process is guided by clinical correlation, not serology alone, and long-term restriction without confirmed benefit is discouraged.

The 184 IgA Food Sensitivity Panel measures serum IgA antibodies to 184 individual food antigens as a functional tool to identify delayed, non-IgE-mediated food reactions. Performed by Alletess Medical Laboratory, it is used in integrative and functional medicine to guide empirical elimination diets in patients with chronic gastrointestinal or systemic symptoms when conventional testing is…

Biomarkers

Blood (serum)

Sample

10–14 business days

Turnaround

Fasting

What is the IgA-184 test?

The 184 IgA Food Sensitivity Panel measures serum IgA antibodies to a broad array of foods, grains, dairy products, meats, seafood, fruits, vegetables, nuts, seeds, spices, and additives. It is ordered by practitioners working within functional, integrative, and naturopathic paradigms who seek to uncover dietary triggers for chronic, non-specific symptoms when conventional testing — coeliac serology, IgE allergy panels, and endoscopy — has been unrevealing or when the clinical picture suggests a delayed, mucosal immune process rather than classic allergy. The panel does not diagnose IgE-mediated food allergy, coeliac disease, or eosinophilic gastrointestinal disorders; it is positioned as a tool to guide empirical elimination diets and to personalise nutrition interventions. Results are interpreted in the context of symptom diaries, gut-health assessment, and sequential reintroduction challenges, not as stand-alone diagnostic evidence.

What does the IgA-184 test measure?

IgA(Food-Specific Immunoglobulin A)

Range: Laboratory-specific classification: negative, borderline, moderate, or high reactivity for each of 184 individual food antigens.Optimal: The laboratory classifies results into negative, borderline, moderate, and high for each antigen; 'optimal' is absent or minimal reactivity, though a low-level response to commonly eaten foods may be physiological and not pathological.Relative units / Optical density

Secretory IgA is the dominant immunoglobulin at mucosal surfaces, synthesised locally by plasma cells in the lamina propria of the gut and transported across the epithelium as a dimeric molecule bound to secretory component. It neutralises luminal antigens, modulates microbial colonisation, and participates in immune exclusion without activating complement or triggering inflammation. Serum IgA — a mix of monomeric and polymeric forms — reflects both mucosal spillover and systemic production; its titre against food antigens is proposed as a marker of repetitive mucosal exposure and loss of oral tolerance, though this interpretation remains contested.

Food-specific IgA testing is used in functional and integrative medicine to identify delayed or non-IgE-mediated food reactions that may contribute to gastrointestinal symptoms, headache, fatigue, and skin or joint complaints. Unlike IgE-mediated allergy, which causes immediate reactions, elevated IgA to a food is interpreted as evidence of ongoing mucosal immune engagement — potentially signalling increased permeability, microbial dysbiosis, or loss of tolerance. The clinical utility of IgA food panels is debated: conventional gastroenterology guidelines do not endorse them for diagnosis, and reactivity does not always correlate with symptoms upon challenge.

Why is the IgA-184 test ordered?

Patients with chronic gastrointestinal symptoms — bloating, altered bowel habit, abdominal pain — in whom coeliac disease and inflammatory bowel disease have been excluded and an empirical elimination diet is planned
Adults or children with recurrent non-specific symptoms (fatigue, headache, joint discomfort, skin complaints) suspected to relate to dietary triggers not captured by standard IgE allergy testing
Assessment of possible non-coeliac gluten or wheat sensitivity, particularly when the patient reports symptom improvement on a gluten-free diet but coeliac serology and biopsy are negative
Functional evaluation of oral tolerance and mucosal immune activation in the context of suspected increased intestinal permeability or dysbiosis
Guidance for a structured elimination–rechallenge protocol when multiple food intolerances are suspected but the clinical history is too diffuse to narrow empirically
Monitoring immune reactivity during gut-restoration or microbiome-rebalancing interventions, where serial panels are used to track change over time

Sample collection and turnaround

Sample type

Blood (serum)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

10–14 business days

Collection notes

Phlebotomy required; specimen is sent to Alletess Medical Laboratory for analysis. The patient should be consuming the foods of interest in their usual diet for at least two to four weeks before testing, as prolonged elimination may reduce detectable IgA titres. Note that selective IgA deficiency affects approximately 1 in 300–700 individuals; if clinical suspicion is high, request measurement of total serum IgA alongside the panel to confirm interpretability.

Specimen requirements

Minimum 5 mL serum in a red-top or serum separator tube. Separate serum from cells and freeze if shipping is delayed beyond 48 hours; IgA antibodies are stable frozen for weeks. Ship with appropriate cold-chain packaging to the specialty laboratory.

What can affect IgA-184 results?

reducesSelective IgA deficiency

Approximately 1 in 300–700 individuals have selective IgA deficiency and produce little or no IgA; the panel will be uninformative in these patients, and IgG or IgG subclass testing may be considered instead.

variableRecent dietary exposure and oral tolerance

IgA titres reflect recent and repetitive mucosal exposure; a food eliminated for weeks or months before testing may yield a false-negative result, while a newly introduced food may not yet have elicited a detectable response.

reducesImmunosuppressive therapy

Corticosteroids, biologics, and other immunosuppressants can dampen antibody production and lower measured IgA reactivity, masking true mucosal immune engagement.

elevatesAcute gastrointestinal infection or inflammation

Acute enteritis, gastroenteritis, or flare of inflammatory bowel disease transiently increases mucosal permeability and polyclonal IgA production, potentially raising titres to multiple foods non-specifically.

variableCross-reactivity between related food proteins

Structural homology between proteins in related foods (for example legumes, tree nuts, or grains) can lead to cross-reactive antibody binding and complicate interpretation of which specific food is the true trigger.

variableLaboratory technique and antigen preparation

Results are method-specific; optical density or relative units are not standardised across laboratories, so values from different platforms cannot be directly compared and reproducibility has not been rigorously validated in the literature.

What do IgA-184 results mean?

Elevated

A moderate or high IgA titre to a specific food is interpreted as evidence of mucosal immune activation against that antigen, suggesting repetitive exposure in the context of impaired oral tolerance, increased permeability, or dysbiosis. The finding is not diagnostic of allergy or intolerance but is used to prioritise foods for a time-limited elimination trial (typically 4–12 weeks), followed by structured reintroduction and symptom tracking. Reactivity to many foods (more than 20–30) raises concern for non-specific polyclonal activation or specimen artifact and warrants clinical correlation.

Normal

Negative or borderline reactivity across the panel suggests that delayed IgA-mediated food reactions are unlikely to be the primary driver of symptoms, though it does not exclude IgE allergy, coeliac disease, or non-immune mechanisms (enzyme deficiencies, FODMAPs, histamine intolerance). Symptoms may warrant investigation along other lines — breath testing for carbohydrate malabsorption, mast-cell evaluation, or gastrointestinal endoscopy.

Reduced

Absent or very low IgA to all tested foods may indicate selective IgA deficiency, recent dietary restriction, or profound immunosuppression. Confirm total serum IgA; if deficient, consider IgG-based food panels or focus on clinical elimination–rechallenge rather than serology.

Note: IgA food panels are not endorsed by major gastroenterology or allergy societies; evidence linking elevated IgA to clinical food intolerance is limited, and reactivity does not always reproduce on blinded food challenge. The test is a functional tool to guide empirical dietary intervention, not a stand-alone diagnostic. Interpretation must be individualised, integrated with symptom diaries and sequential reintroduction, and never used to impose long-term restrictive diets without clinical correlation. Patients should understand that a positive result does not mean lifelong avoidance is required.

Frequently asked questions

IgE testing detects immediate, potentially life-threatening food allergy mediated by mast cells and histamine release. IgA testing measures mucosal antibodies proposed to reflect delayed, non-IgE reactions and loss of oral tolerance; the two are not interchangeable and address different clinical questions.

How to access the IgA-184 test

The IgA-184 reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

Stapel SO, et al. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy. (2008)
Catassi C, et al. Diagnosis of non-celiac gluten sensitivity: the Salerno Experts' Criteria. Nutrients. (2015)
Bischoff SC, et al. Intestinal permeability — a new target for disease prevention and therapy. BMC Gastroenterol. (2014)
Turnbull JL, et al. The role of the immune system in food intolerance. Curr Allergy Asthma Rep. (2015)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.